Pandemija COVID-19 paralizirala je transplantacijske programe širom svijeta, uz visoke stope smrtnosti u populaciji bolesnika s transplantiranim bubregom. Suočeni s nepoznatim patogenom svjedočimo čitavom nizu manje ili više uspješnih pokušaja liječenja. Bolesnici s transplantiranim bubregom su posebno ugrožena skupina s obzirom na kronično stanje imunosupresije. Dodatan problem u liječenju COVID-19 predstavlja problem mogućih interakcija lijekova koji se rabe u liječenju SARS-CoV-2 s imunosupresivima, kao i rizik akutnih odbacivanja prilikom značajnih smanjivanja imunosupresije. Ponovno oživljavanje transplantacijskih programa zahtijevat će pažljivu procjenu rizika i dobrobiti za svakoga pojedinog bolesnika uz promišljanje načina uspostave međunarodne razmjene organa. Potrebna su daljnja istraživanja kako bi se odredio optimalan način liječenja SARS-CoV-2 u bolesnika s transplantiranim bubregom.The COVID-19 pandemic has paralyzed renal transplant programs worldwide, with high mortality rates in renal transplant patients. Faced with an unknown pathogen, we have witnessed numerous treatment attempts that have been more or less effective. Renal transplant recipients are at increased risk for morbidity and mortality from COVID-19 given their chronic immunocompromised state. Additional complications are potential interactions in drugs used for treatment of SARS-CoV-2 and immunosuppressive medications, as well as risk of acute allograft rejection associated with reduction of immunosuppression. The revival of renal transplant programs will require careful assessment of individual risk-to-benefit ratio for each patient, with step-by-step reintroduction of international organ exchange. Further studies are needed to determine optimal treatment of SARS-CoV-2 in renal transplant recipients
